Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 21;13(3):e12280.
doi: 10.1002/pul2.12280. eCollection 2023 Jul.

Increased serum activin A level in congenital heart disease-associated pulmonary artery hypertension: A comparative study from the COHARD-PH registry

Muhammad R Hadwiono  1   2 , Anggoro B Hartopo  1 , Widya Wasityastuti  3 , Dyah W Anggrahini  1 , Gusty R T Ryanto  4 , Noriaki Emoto  4   5 , Lucia K Dinarti  1
Affiliations

Increased serum activin A level in congenital heart disease-associated pulmonary artery hypertension: A comparative study from the COHARD-PH registry

Muhammad R Hadwiono et al. Pulm Circ. .

Abstract

Activin A, a member of TGF-β superfamily, has been implicated in the pathogenesis of pulmonary artery hypertension (PAH). PAH due to congenital heart disease (CHD-PAH) is a major problem in developing countries. Activin A may have a role in PAH development and progression among uncorrected CHD. In this comparative study, serum activin A level was significantly increased in subjects with uncorrected CHD without the presence of PH and were more significantly risen in CHD-PAH, as compared to control. The utilization of serum activin A measurement seems promising to identify uncorrected CHD patients with PAH development and progression.

Keywords: NT‐pro BNP; biomarkers; congenital heart disease; endothelin 1.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The incremental increase of serum activin A level among subject groups (p value from the Student T test, analyzed between groups).
Figure 2
Figure 2
(a) Positive correlation between activin A and NT‐proBNP levels in subjects with congenital heart disease (CHD) (both CHD‐noPH and CHD‐PAH) (r = 0.876, p < 0.001). (b) Positive correlation between activin A and NT‐proBNP levels in subjects with CHD‐pulmonary artery hypertension (PAH) (r = 0.900, p < 0.001).
See this image and copyright information in PMC

References

    1. Balistrieri A, Makino A, Yuan JXJ. Pathophysiology and pathogenic mechanisms of pulmonary hypertension: role of membrane receptors, ion channels and Ca2+ signaling. Physiol Rev. 2023;103(3):1827–1897. - PMC - PubMed
    1. Fessel JP, Loyd JE, Austin ED. The genetics of pulmonary arterial hypertension in the post‐BMPR2 era. Pulm Circ. 2011;1(3):305–319. - PMC - PubMed
    1. Guignabert C, Humbert M. Targeting transforming growth factor‐β receptors in pulmonary hypertension. Eur Respir J. 2021;57(2):2002341. - PubMed
    1. Ryanto GRT, Ikeda K, Miyagawa K, Tu L, Guignabert C, Humbert M, Fujiyama T, Yanagisawa M, Hirata K, Emoto N. An endothelial activin A‐bone morphogenetic protein receptor type 2 link is overdriven in pulmonary hypertension. Nat Commun. 2021;12(1):1720. - PMC - PubMed
    1. Kudryashova T, Shen Y, Pena A, Cronin E, Okorie E, Goncharov D, Goncharova E. Inhibitory antibodies against activin A and TGF‐β reduce self‐supported, but not soluble factors‐induced growth of human pulmonary arterial vascular smooth muscle cells in pulmonary arterial hypertension. Int J Mol Sci. 2018;19(10):2957. - PMC - PubMed